MaxCyte vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how MaxCyte (MXCT) and Abbott Laboratories (ABT) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees MaxCyte as the less overvalued of the two: MaxCyte trades at $1.18 versus a fair value of $0.82 (-31%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
MaxCyte
MXCT · USD · Health Care
-31%
upside to fair value
overvalued
Price$1.18
Fair Value$0.82
Quality36/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
MaxCyteAbbott Laboratories
Valuation
—P/E (TTM)27.7×
4.02×P/S (TTM)3.89×
0.76×P/B3.36×
—EV/EBITDA15.1×
—PEG1.47×
Profitability
-121%Net margin14%
-64%Operating margin13%
-21%Return on equity12%
-11%Return on assets6%
Growth
-7%Revenue growth (YoY)8%
-9.3%Avg. growth/yr (3Y)0.5%
4.8%Avg. growth/yr (5Y)5.1%
Balance & size
0.03×Debt / equity0.19×
$130MMarket cap$175B
expensiveGrowth qualityhealthy
Abbott Laboratories leads: 2 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
MaxCyteof which business quality 36 · market factors 30Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
5
50
Quality GrowthAre margins and returns improving?
20
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
94
65
Low VolatilityCalm price path (market factor)
5
83
MomentumPrice trend over the last 3–12 months (market factor)
56
40
52W MomentumDistance to the 52-week high (market factor)
16
33
Net IssuanceBuybacks instead of dilution
66
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
MaxCyte
Asset-Based$1.07
1 of 1 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
MaxCyte
Bear $0.54Fair Value $0.82Bull $1.02
$1.18 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
MaxCyte · Health Care
Quality score36 · bottom 25%
Fair value upside-31% · below median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees MaxCyte as the less overvalued of the two: MaxCyte trades at $1.18 versus a fair value of $0.82 (-31%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
